June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Baseline perimetry in Pro-EYS and correlation with other measures of disease severity
Author Affiliations & Notes
  • Rachel M Huckfeldt
    Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Rachel Huckfeldt AGTC, Annexon, Intergalactic Therapeutics, ProQR, Regeneron, Sunovion, Vida Ventures, Code C (Consultant/Contractor), AGTC, Biogen, Foundation Fighting Blindness, MeiraGTx, ProQR, Spark, Code F (Financial Support), Intergalactic Therapeutics, Code I (Personal Financial Interest), Choroideremia Research Foundation, Code S (non-remunerative)
  • Footnotes
    Support  Foundation Fighting Blindness
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4632. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rachel M Huckfeldt; Baseline perimetry in Pro-EYS and correlation with other measures of disease severity. Invest. Ophthalmol. Vis. Sci. 2023;64(8):4632.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To address limited data characterizing retinal degeneration related to biallelic EYS variants, the Foundation Fighting Blindness Consortium is conducting a 4-year multicenter, international natural history study: Rate of Progression in EYS-Related Retinal Degeneration (Pro-EYS). Here we report baseline data on static perimetry (SP) and its relationship with participant characteristics and other outcome measures.

Methods : SP was performed by participants with baseline visual acuity ≥ 20/400. Summary SP measures were total hill of vision (VTOT), hill of vision (HOV) in the central 30° (V30), VTOT-V30 (VPERIPH), and mean sensitivity (MS). Intra-class correlation coefficients (ICC) and repeatability coefficient (RC) were used to assess reproducibility of SP between tests 1 and 2. Mixed effects linear models assessed the association of demographic and clinical characteristics with VTOT. Associations among SP measures and with other functional and structural measures were assessed with Spearman correlation coefficients (rs).

Results : Ninety-six participants (52% female) with median age of 42 years and disease duration of 19 years were included in analyses. The median and interquartile range were 6.3 (2.0, 16.6) dB-sr for VTOT, 4.2 (1.7, 9.5) dB-sr for V30, 1.4 (0.0, 7.0) dB-sr for VPERIPH, and 5.3 (2.4, 9.9) dB-sr for MS. Three-dimensional (3-D) HOV images illustrate the range of VTOT (Figure 1). The RC for VTOT was 5.7 dB-sr with high subject-level concordance between tests 1 and 2 (ICC= 0.96). SP measures were strongly correlated with each other (rs=0.83 to 0.98; Figure 2) and with microperimetry MS (rs=0.55 to 0.81, all P < 0.001). Mild to moderate correlations were observed between SP and other measures including best corrected visual acuity, full-field stimulus threshold, full-field electroretinography amplitudes, and ellipsoid zone area. Higher VTOT values were associated with shorter disease duration (P = 0.03) and phakia (P = 0.01).

Conclusions : VTOT decreases with disease duration in EYS-associated retinal degeneration and shows high repeatability. The correlation of VTOT with other SP and outcome measures suggests it is a good summary measure of disease severity.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

 

3-D HOV images for 2 participants

3-D HOV images for 2 participants

 

Matrix plot for SP measures. Panels along the diagonal show the histograms with density curves; upper panels show Spearman correlation coefficients; lower panels show scatterplots with loess smooth curves.

Matrix plot for SP measures. Panels along the diagonal show the histograms with density curves; upper panels show Spearman correlation coefficients; lower panels show scatterplots with loess smooth curves.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×